GlassScriptPhysician profile
Olujimi A Adefisan
NPI 1790947216
$13,632.88
in general payments reported to CMS, 2019-2025
27 companies · $2,482 in 2025
The $2,482 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $429 · 2021: $1,705 · 2022: $2,337 · 2023: $2,599 · 2024: $2,390 · 2025: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,424 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,423.54 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,787.20 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,632.24 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,358.87 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,276.34 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,139.14 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,130.13 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,018.13 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $956.14 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $948.53 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $421.94 | 2019-2022 | |
| Corium, LLC | $413.39 | 2021-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $341.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $161.58 | 2024-2025 | Cobenfy |
| Allergan, INC. | $156.93 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $148.91 | 2023-2025 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $143.69 | 2023-2025 | Auvelity |
| Indivior INC. | $136.63 | 2020-2025 | Sublocade, Perseris |
| Noven Therapeutics, LLC | $113.33 | 2021-2024 | Secuado, Xelstrym |
| Shire North American Group INC | $66.38 | 2019 | |
| Idorsia Pharmaceuticals US INC | $58.08 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $47.94 | 2023-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $37.75 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $36.14 | 2019-2020 | |
| Biogen, INC. | $27.81 | 2023 | |
| Acadia Pharmaceuticals INC | $25.48 | 2025 | Nuplazid |
| Almatica Pharma LLC | $24.83 | 2024 | Loreev Xr |
| Bioxcel Therapeutics, INC. | $23.56 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olujimi Adefisan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.